What are the treatment options for Raynaud's phenomenon affecting the hands?

Treatment of Raynaud's Phenomenon in the Hands

For Raynaud's phenomenon affecting the hands, calcium channel blockers (particularly nifedipine) should be first-line pharmacologic therapy, combined with non-pharmacological measures including cold avoidance, use of gloves and heating devices, and physical exercise. 1, 2

Treatment Algorithm

Non-Pharmacological Management (All Patients)

Cold protection is foundational and should be implemented immediately:

• Use gloves and heating devices for hands
• Avoid direct contact with cold surfaces
• Thoroughly dry skin after exposure to moisture
• Maintain overall body warmth (not just hands)
• Physical exercise should be incorporated to improve overall vascular function 2

Recent RCT evidence confirms gloves reduce Raynaud's burden, though specialized silver fiber gloves offer no advantage over conventional ones 2.

Pharmacological Management

Step 1: Calcium Channel Blockers

• Nifedipine remains the "gold standard" first-line agent 3, 4
• Long-acting or "retard" preparations reduce adverse effects (ankle swelling, headache, flushing) while maintaining efficacy
• Alternative: Diltiazem has fewer adverse effects but reduced efficacy compared to nifedipine 4

Step 2: Add PDE5 Inhibitors if inadequate response

• Phosphodiesterase-5 inhibitors (e.g., sildenafil) should be added when calcium channel blockers alone are insufficient 1, 4
• These agents reduce symptom frequency and improve ulcer healing 4, 5

Step 3: For Digital Ulcers or Critical Ischemia

• Intravenous iloprost (prostacyclin analogue) is standard of care for digital ulcers and critical digital ischemia 1, 4, 5
• This is considered second-line therapy for patients with markedly impaired quality of life or at risk for tissue loss 5

Step 4: Prevention of Recurrent Digital Ulcers (Secondary Raynaud's)

• Endothelin receptor antagonists (e.g., bosentan) for prevention of future ulcers in systemic sclerosis patients with recurrent digital ulcers 4, 5
• Note: The 2025 EULAR guidelines found conflicting evidence for ERAs in treating Raynaud's phenomenon itself and made no recommendation for this indication 1

Additional Considerations

Antiplatelet therapy:

• Low-dose aspirin recommended for all patients with secondary Raynaud's due to structural vessel damage 5

Refractory cases:

• Botulinum toxin injection shows promise with 82% probability of pain improvement and 79% probability of digital ulcer healing, though evidence remains mixed 6, 7
• Digital sympathectomy may be considered for critical digital ischemia, though symptom recurrence is common 3, 4

Important Caveats

Primary vs. Secondary Raynaud's distinction matters:

• Primary Raynaud's typically has milder symptoms and may respond adequately to non-pharmacological measures alone
• Secondary Raynaud's (especially with systemic sclerosis) usually requires pharmacologic intervention and more aggressive management 3, 5

Avoid vasospastic drugs that can trigger or worsen symptoms 4

Pain management is notably absent from current treatment guidelines despite being a significant patient concern—this represents a gap in guideline-based care 8

Fluoxetine was deprioritized in the 2025 EULAR update and is no longer recommended 1

The evidence strongly supports a stepwise approach starting with non-pharmacological measures for all patients, adding calcium channel blockers as first-line pharmacotherapy, then escalating to PDE5 inhibitors and ultimately intravenous prostacyclins for severe disease or digital complications.